Tango Therapeutics, Inc.
TNGXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeTango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company carries a $4.83B market cap, placing it firmly in the mid-cap category. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.
Market Cap
$4.83B
Beta
1.13
P/E (TTM)
—
P/E (Fwd)
-18.77
EPS (TTM)
$-0.87
EPS (Fwd)
$-1.58
ROE
-38.4%
ROA
-20.7%
Cash
$379.8M
Total Debt
$32.8M
Free CF
-$68.2M
52W Change
379.9%
Annual Financials
Cash vs Debt
Tango Therapeutics, Inc. holds $379.8M in cash against $32.8M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$68.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -38.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $24.9M (2022) to $62.4M (2025), reflecting a 151% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing TNGX.